Mira Pharmaceuticals Inc(MIRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 25 at 7:28 PM ET (Korea 9/26 08:28)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.38 | Insider Own | 7.92% | Shs Outstand | 42.0M | Perf Week | 8.13% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 38.7M | Perf Month | 20% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.03 | Inst Own | 5.51% | Short Float | 1.16% | Perf Quarter | -10.89% |
| Income | -0.03B | P/S | - | EPS this Y | - | Inst Trans | 1.25% | Short Ratio | 0.78 | Perf Half Y | -15.09% |
| Sales | 0.00B | P/B | 4.63 | EPS next 5Y | 32.7% | ROA | -684.27% | Short Interest | 0.45M | Perf YTD | -40.4% |
| Book/sh | 0.19 | P/C | 4.66 | EPS past 3/5Y | -41.42% -211.56% | ROE | -710.85% | 52W High | -63.27% ($2.45) | Perf Year | -30.77% |
| Cash/sh | 0.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -380.24% | 52W Low | 50% ($0.60) | Perf 3Y | -79.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -186.73% | Gross Margin | - | Volatility(W/M) | 8.23% 9.94% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 200.08 | EPS Q/Q | 68.18% | Profit Margin | - | RSI (14) | 60.31 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 200.08 | Sales Q/Q | - | SMA20 | 12.41% ($0.8) | Beta | 1.51 | Target Price | $6.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | 13.12% ($0.8) | Rel Volume | 0.17 | Prev Close | $0.84 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -15.65% ($1.07) | Avg Volume(3M) | 0.57M | Price | $0.9 |
| IPO | 2023/8/3 | Option/Short | No/Yes | Trades | 442 | Volume | 95,119 | Change | 7.21% |
🧠 This is a biopharmaceutical company developing marijuana-like new drugs. Its lead candidate, MIRA-55, is a next-generation painkiller designed to retain marijuana's pain-relieving effects while eliminating hallucinogenic side effects. The company is researching applications for neuropathic pain, anxiety, and early-stage dementia, and has received confirmation from the DEA that it is not a controlled substance.
Over the past 1 year, on the lower side
63% below its 1-year high.
Traded less than usual That is 17% of its average volume.
MIRA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +32.7% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -80.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #19 of 21 in the industry
Based on market cap of $38M.
FAQ
What kind of company is MIRA?
MIRA belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of MIRA?
The market cap of MIRA is approximately $38M, ranking 5,062 within its sector.
What is the 52-week high and low for MIRA?
MIRA has recorded a 52-week high of $2.45 and a low of $0.60.
